Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.


30 Sep 2019


Poster Display session 3


Tumour Site

Prostate Cancer


Susanne Osanto


Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248


S. Osanto1, C. Alvarez1, H. Bloem2, T. van der Hulle1, M. Jonker1, M. Ozdemir2, K. Goossens3, M. Wijffelman3, R. Pelger4, H. Van Poppel5, K. Burggraaf6

Author affiliations

  • 1 Oncology, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL
  • 2 Radiology, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL
  • 3 Urology, Alrijne Hospital, 2353 GA - Leiderdorp/NL
  • 4 Urology, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL
  • 5 Urology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 6 Oncology, Center for Human Drug Research, Leiden/NL


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5795


AR-inhibition with Enzalutamide may be an attractive alternative for 1L treatment of men with hormone-sensitive prostate cancer compared to androgen deprivation therapy (ADT). There is an unmet need for robust, reproducible imaging technology allowing accurate quantification and qualification of bone plus soft tissue metastases and assessment of early tumour responses to novel agents. PET/CT or WB MRI imaging offer advantage over traditional bone and CT scans.


Sixty patients with metastatic hormone-sensitive PC were included in this prospective cohort study. Patients received Enzalutamide 160 mg once daily until progression of disease. Imaging tests were performed at baseline and bone scintigraphy and CT repeated at 3 month intervals, 18F-choline PET/CT at 2 weeks, 2, 6, 9 and 12 months and WB-MRI at 6 and 12 months. Enumeration of circulating tumor cells and quality of life assessments were secondary outcomes.


Sixty patients with a median age of 72 yrs (range 57 − 85) and a median PSA of 62.8 μg/L (range 3-622) were enrolled. This study is ongoing; all of the first 50 patients experienced a ≥ 50% PSA decline and 49 a ≥ 90% PSA decline. Choline-PET imaging and WB MRI were more frequently able to detect metastases and measure favorable responses than bone scan or CT thorax and abdomen. Investigator and central review of all imaging results are ongoing. Treatment was well tolerated.


18F-choline PET/CT and WB-MRI were superior in detection of bone and lymph node metastases and 18F-choline PET/CT was useful for early response detection already at 2 weeks. Based on results both 18F-choline-PET and WB MRI imaging have great clinical utility in aiding clinicians treating men with hormone-sensitive metastatic prostate cancer.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

European Uro-Oncology Group (EUOG).


Astellas Pharma.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.